Search Results

CathVision Unveils ECGenius 3.1 To Improve Workflows and Optimize EGM AI Analyses

CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, announced the launch of ECGenius 3.1, an advanced version of the ECGenius™ System software.

December 12, 2023

·

3 min read

CathVision Secures $9 Million in Funding to Accelerate Adoption of ECGenius System & CARDIALYTICS AI-Suite

CathVision, a medical technology company developing innovative electrophysiology solutions designed to support clinical decision making in the EP lab, today announced its most recent financing round of $9 million from investors.

July 18, 2023

·

3 min read

CathVision Secures FDA Clearance of First & Only EP Recording System with AI Algorithm to Measure Success of Cardiac Ablation

CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA clearance and commercial availability of the PVI AnalyzerTM and Signal ComplexityTM algorithms.

August 15, 2023

·

3 min read

CathVision’s ECGenius System to be Featured at HRS 2023 Rhythm Theater Symposium and Scientific Presentations

CathVision today announced an extensive slate of educational opportunities and scientific sessions at this year’s Heart Rhythm conference demonstrating the significant impact of the ECGenius™ System and potential benefits of AI-based analytics.

May 15, 2023

·

5 min read

CathVision Announces Key Milestones in Advance of ECGenius Commercial Launch

CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision-making in the EP lab, is proud to announce the achievement of significant milestones demonstrating both the clinical and commercial success of the ECGenius™ System.

March 28, 2023

·

4 min read

Progressing Clinical Evidence: CathVision Announces First Patient Enrolled In Persistent AF Study at OLV Hospital Aalst

CathVision announced initial patient enrollment of a follow-on clinical study to demonstrate the value of the Signal Complexity™ algorithm at OLV Hospital Aalst in Belgium led by Dr. Tom De Potter.1 The first patient has been enrolled.

April 17, 2023

·

3 min read

CathVision Announces Initiation of Clinical Study Evaluating Signal Complexity Algorithm

CathVision, a medical technology company developing innovative electrophysiology solutions to enhance clinical decision-making in the EP lab, today announced the investigation of the Signal Complexity™ algorithm designed to visualize and quantify atrial fibrillation (AF) complexity parameters in patients with persistent AF.

November 2, 2022

·

3 min read

CathVision Announces Close Of $7.2 Million Financing Round

CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the company has secured $7.2 million in funding from existing investors.

August 17, 2022

·

2 min read

CathVision Announces Completion of Patient Enrollment at First U.S. Clinical Trial Evaluating High-Fidelity, Low-Noise EP Recording Technology

CathVision, today announced the completion of patient enrollment in the CathVision ECGenius System clinical evaluation study at the University of Vermont Medical Center.

April 26, 2022

·

3 min read

CathVision Announces FDA Clearance of ECGenius™ High-Fidelity, Low-Noise EP Recording Technology

CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA 510(k) clearance of the ECGenius EP Recording System.

May 4, 2022

·

3 min read